Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.

Conteduca, V; Wetterskog, D; Sharabiani, M T A; Grande, E; Fernandez-Perez, M P; Jayaram, A; Salvi, S; Castellano, D; Romanel, A; Lolli, C; Casadio, V; Gurioli, G; Amadori, D; Font, A; Vazquez-Estevez, S; González Del Alba, A; Mellado, B; Fernandez-Calvo, O; Méndez-Vidal, M J; Climent, M A; Duran, I; Gallardo, E; Rodriguez, A; Santander, C; Sáez, M I; Puente, J; Gasi Tandefelt, D; Wingate, A; Dearnaley, D; Demichelis, F; De Giorgi, U; Gonzalez-Billalabeitia, E; Attard, G

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/31947

Title:	Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
Authors:	Conteduca, V Wetterskog, D Sharabiani, M T A Grande, E Fernandez-Perez, M P Jayaram, A Salvi, S Castellano, D Romanel, A Lolli, C Casadio, V Gurioli, G Amadori, D Font, A Vazquez-Estevez, S González Del Alba, A Mellado, B Fernandez-Calvo, O Méndez-Vidal, M J Climent, M A Duran, I Gallardo, E Rodriguez, A Santander, C Sáez, M I Puente, J Gasi Tandefelt, D Wingate, A Dearnaley, D Demichelis, F De Giorgi, U Gonzalez-Billalabeitia, E Attard, G View more
Keywords:	abiraterone androgen receptor biomarker castration-resistant prostate cancer enzalutamide plasma DNA View more
Mesh:	Adult Aged Aged, 80 and over Androstenes Antineoplastic Agents, Hormonal Biomarkers, Tumor Circulating Tumor DNA DNA Mutational Analysis Disease Progression Disease-Free Survival Europe Humans Kaplan-Meier Estimate Male Middle Aged Multiplex Polymerase Chain Reaction Multivariate Analysis Mutation Odds Ratio Patient Selection Phenylthiohydantoin Precision Medicine Predictive Value of Tests Proportional Hazards Models Prospective Studies Prostatic Neoplasms, Castration-Resistant Receptors, Androgen Risk Factors Time Factors Treatment Outcome View more
Issue Date:	1-Jul-2017
Citation:	Ann. Oncol..2017 Jul;(28)7:1508-1516
Abstract:	There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC.
PMID:	28472366
URI:	https://hdl.handle.net/20.500.12530/31947
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos Fundaciones e Institutos de Investigación > IIS H. U. Clínico San Carlos > Artículos Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:

File	Description	Size	Format
PMC5834043.pdf		341.62 kB	Adobe PDF	View/Open

Show full item record